In-vitro diagnostic is an advanced method that provides new tools to find disease diagnosis and treatment. In the United States, the growing prevalence of chronic and infectious diseases has spurred the development of the in-vitro diagnostics (IVD) market. In-vitro diagnostics (IVDs) in the US is considerably more than simple assays conducted in test tubes and examining glass dishes under microscopes. These instruments used to analyze body fluids and tissue samples collected from a patient. The United States In-vitro Diagnostics Market Size was worth US$ 26.9 Billion in 2020.
Further In-Vitro diagnostics are used in large-scale population screenings such as for cervical cancer. As well as predicting, whether a particular medicine or therapy would work on a patient. Patients with diabetes use IVDs to test their blood glucose levels regularly. At the same time it is also used to make or confirm a medical diagnosis, such as confirming a pregnancy or testing infectious diseases like HIV or hepatitis. According to Renub Research, United States In Vitro Diagnostics Market will be US$ 35.3 Billion opportunities by 2026.
The United States In-Vitro Diagnostics have a vast product ranges. The reagents segment fastest-growing product in the In-Vitro Diagnostics market as the increasing volume of tests and the rise in R&D initiatives pertaining to reagents. Instrument product is also seen to dominate the market in the forecast period because of rising approval of COVID-19 tests for emergency use by the regulatory authorities. In the United States, the In-vitro diagnostics market is currently in the South of the country, followed by the West being second. As per our research findings, United States IVD Industry will further grow with a CAGR of 4.63% during 2020-2026.
Coronavirus Impact on IVD Industry of United States
The in-vitro diagnostics industry has seen a huge spurt in demand due to the Covid-19 Pandemic. Primary assays used for COVID-19 detection employ the RT-PCR technique. Although the traditional test takes 5 to 6 hours to produce a result, POC assays (Rapid Antigen Test) have drastically decreased the time. Thus, COVID-19 presents a significant opportunity for the IVD industry’s leading stakeholders. As a result, the overall impact of the COVID-19 pandemic on substantial companies in the in vitro diagnostics sector remained positive. Few organizations experiencing a setback due to the lockdown have decreased the amount of regular IVD tests completed across the United States. However, the rapid demand for newly available emergency use permitted IVD tests for COVID-19 detection offsets this negative impact.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND)
Email:Â [email protected]
Web:Â https://www.renub.com
Follow on Linkedin:Â https://www.linkedin.com/company/renub-research
